Precision oncology is an approach that uses molecular profiling to identify the specific genetic alterations driving a patient's cancer, enabling targeted therapies tailored to the individual patient.
Traditional biopsy methods often require invasive procedures and may not capture the full genetic profile of a patient's cancer. Liquid biopsies offer a non-invasive alternative, providing real-time monitoring of disease progression and response to therapy without the need for repeated invasive procedures.
Liquid biopsies involve collecting blood samples from patients, which are then analyzed using advanced sequencing technologies. These techniques can detect circulating tumor cells and fragments of DNA (ctDNA) that provide information about the genomic landscape of the cancer. This data is used to tailor treatment plans for each patient.
Manufacturing involves developing and validating liquid biopsy assays, which include sample collection devices, extraction kits, and sequencing platforms. These components are typically produced in specialized laboratories with stringent quality control measures.
The build process includes designing the assay to target specific genetic markers, optimizing the extraction of ctDNA from blood samples, and integrating this with high-throughput sequencing technologies. Validation studies are conducted to ensure accuracy and reliability before clinical use.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.